How to access Alecensa for ALK-positive non-small-cell lung cancer from Oman: 2026 pathway via Oman oncology and regional referral
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Oman's adult medical oncology services run out of Sultan Qaboos University Hospital (SQUH) (KHUH), Royal Hospital Muscat, and Muscat Private Hospital, with established referral pathways to KFSHRC Riyadh and the NCCCR at Hamad Medical Corporation in Doha for cases requiring deeper subspecialty infrastructure. Alecensa (alectinib) is registered with Oman's Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) and is part of standard first-line management for confirmed ALK-positive non-small cell lung cancer (NSCLC). For an Omani adult with newly diagnosed ALK-positive metastatic NSCLC or with completely resected ALK-positive stage IB to IIIA disease, the operational reality is that Oman's molecular pathology and oncology infrastructure handle the core pathway in-country, with cross-border options to Saudi Arabia, Qatar, or the UAE available where the home centre prefers a partnership review.
This page explains how the pathway works in 2026 for a Oman-resident adult: who qualifies, where the diagnostic and molecular workup happens, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in OMR, what to monitor on therapy, and how the multi-year treatment course settles into an Omani family's life.
Why Alecensa, and why now
Alecensa is alectinib, a second-generation, central-nervous-system-penetrant ALK tyrosine kinase inhibitor developed by Roche with Chugai Pharmaceutical. FDA first-line approval came in November 2017 based on the ALEX trial (median progression-free survival 34.8 months on Alecensa versus 10.9 months on crizotinib; CNS objective response rate 81 percent versus 50 percent). The April 2024 label expansion added adjuvant treatment for stage IB to IIIA ALK-positive NSCLC after complete resection, based on the ALINA trial (disease-free survival hazard ratio 0.24 favouring Alecensa).
For an Omani patient with confirmed ALK-positive NSCLC, Alecensa is the standard-of-care first-line ALK TKI under most institutional protocols followed by KHUH, Royal Hospital Muscat, and Muscat Private Hospital. The eligibility gatekeeper is biomarker confirmation: documented ALK rearrangement.
What Alecensa is, in plain language
Alecensa is an oral capsule. Four 150 mg capsules per dose, twice daily, twelve hours apart, with food. Total daily dose 1,200 mg. Room temperature storage. No infusion, no inpatient stay, no certified-centre requirement. The prescribing oncologist writes the first prescription; the dispensing pharmacy (institutional or partnered specialty) fills a 30-day or 60-day supply; the patient takes Alecensa at home.
For metastatic disease, treatment is until progression or intolerable toxicity. For the adjuvant indication, treatment is fixed at 2 years.
The mechanism: ALK rearrangement produces a constitutively active fusion protein (most commonly EML4-ALK). Alecensa binds the ATP-binding pocket of the ALK kinase domain approximately 10-fold more potently than crizotinib, achieves meaningful CNS exposure, and remains active against most resistance mutations except G1202R.
The biomarker requirement
The eligibility gate is documented ALK rearrangement by IHC, FISH, or NGS. ALK IHC capability exists at the major Oman pathology services (KHUH, Royal Hospital Muscat, Muscat Private Hospital), and confirmatory FISH or NGS is typically routed to KFSHRC molecular pathology in Riyadh, NCCCR molecular pathology in Doha, or to international reference labs (Caris Life Sciences, Foundation Medicine) for complex panels or liquid biopsy. Turnaround for the full workup is typically 2 to 6 weeks depending on the route.
If the original diagnostic biopsy did not include ALK testing, archived tissue submission or re-biopsy is standard.
Eligibility at a Oman oncologist's clinic
For Oman-resident patients, the medical oncology service applies the FDA, EMA, and major-guideline criteria:
1. Histologically confirmed NSCLC. 2. Confirmed ALK rearrangement by IHC, FISH, or NGS. 3. For metastatic indication: stage IV disease confirmed by contrast CT, PET-CT, and brain MRI. 4. For adjuvant indication: stage IB (tumour 4 cm or larger) through IIIA disease with complete resection and ALK rearrangement on resected tissue. 5. Baseline labs: CBC, comprehensive metabolic panel including LFTs, creatine kinase, bilirubin. 6. Baseline ECG with QTc and heart rate. 7. Baseline pulmonary assessment. 8. Pregnancy and lactation screen; contraception documented for women of reproductive potential. 9. Drug interaction screen including herbal products and grapefruit.
An Omani patient should arrive at the oncology referral with the most recent pathology, imaging, and prior treatment history. Reserve Meds organises the documentation pack.
Oman prescribing and dispense picture, plainly
In 2026 Oman oncology centres with active Alecensa prescribing and refill experience include:
- Sultan Qaboos University Hospital (SQUH) (KHUH): oncology service with medical oncology and pathology capability. - Royal Hospital Muscat: MoH flagship; medical oncology and the national cancer registry interface. - Muscat Private Hospital: private-sector oncology.
The pathway:
1. Diagnosis and molecular confirmation: at the diagnosing centre's pathology lab; complex molecular work routed to KFSHRC Riyadh, NCCCR Doha, or international reference labs. 2. Multidisciplinary tumour board review: KHUH and Royal Hospital Muscat run thoracic / molecular tumour boards. Documentation of rationale and treatment plan. 3. MoH treatment-abroad option: for cases where the treating physician prefers regional centre management or where subspecialty molecular interpretation is wanted, the MoH treatment-abroad office maintains referral relationships with KFSHRC Riyadh and Cleveland Clinic Abu Dhabi; the cross-border referral mechanism is mature and well-tested. 4. Insurance pre-authorisation: AXA Gulf, Oman National Insurance, GIG Oman, and regional Bupa products handle Alecensa on prior-authorisation; documentation requirement is ALK rearrangement and MDT recommendation. 5. Pharmacy dispense: the prescribing centre's pharmacy fills a 30-day or 60-day supply. Roche commercial supply runs through Cigalah and other regional distributors. 6. Refill cycle: monthly thereafter, with monitoring lab documentation.
Cost expectation in OMR
US list price (2026) for Alecensa at 600 mg twice daily is approximately USD 14,000 to USD 16,000 per 30-day supply, annual approximately USD 170,000 to USD 190,000. At indicative 2026 cross rates, a 30-day supply at USD 15,000 is approximately OMR 5,650, and annual cost at USD 180,000 is approximately OMR 68,000. A 2.5-year metastatic course is approximately OMR 170,000 cumulative drug cost; a 2-year adjuvant course is approximately OMR 136,000.
For Omani-national families on MoH coverage, Alecensa is dispensed through the institutional formulary at KHUH or Royal Hospital Muscat. For expatriate residents and self-pay families, the pharmacy issues a separated quote: drug cost, monitoring labs, imaging, oncologist visits, and any Reserve Meds coordination fee disclosed in writing.
Monitoring on therapy
- Liver function tests: every 2 weeks for the first 3 months, then monthly. - Creatine kinase: every 2 weeks for the first month, then every 4 weeks. - Heart rate and ECG: as clinically indicated. - Pulmonary symptoms: any new or worsening dyspnoea, cough, or fever triggers HRCT and pulmonology input for ILD workup. - Photosensitivity counselling: sun avoidance and high-SPF sunscreen. - Disease assessment: contrast CT or PET-CT every 8 to 12 weeks; brain MRI every 12 weeks if CNS metastases at baseline.
Religious, ethical, and family-logistics framing
Alecensa is an oral small molecule. No animal-source material, no donor cells. Halal acceptability is not in question. The classical Islamic jurisprudential framework for chronic medication in life-threatening illness endorses the treatment shape.
The family-logistics burden sits in the chronicity and adherence: twice-daily dosing with food for 2 to 3 years (metastatic) or 2 years (adjuvant), with monitoring labs every 2 weeks initially. Adherence support and family co-monitoring are part of the practical handoff at first refill.